Skip to content
PARTICIPER À UNE ÉTUDELISTE DE DIFFUSION
X page opens in new window
AB SCIENCE
Discipline serving the patients
AB SCIENCE
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in sickle cell disease
    • Masitinib in neurodegenerative disorders
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Sickle Cell Disease
      • Alzheimer’s Disease
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Articles of Incorporation
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • FR
  • EN
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in sickle cell disease
    • Masitinib in neurodegenerative disorders
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Sickle Cell Disease
      • Alzheimer’s Disease
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Articles of Incorporation
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Daily Archives: 6 November 2019

You are here:
  1. Home
  2. 2019
  3. November
  4. 06

First presentation of preclinical results for compound AB8939 in the 61st ASH Annual Meeting

2019By Alexis BERNARD6 November 2019

06/11/2019 – AB Science announces the first presentation of preclinical results of compound AB8939 in the 61st ASH Annual meeting online program

Financing agreement to pre-finance the 2019 research tax credit

2019By Alexis BERNARD6 November 2019

06/11/2019 – AB Science has signed a financing agreement in order to pre-finance the 2019 research tax credit

© 2026 AB SCIENCE
Go to Top